

For safer pregnancies.

Pre-Eclampsia management in 2T/3T with PIGF or sFlt-1/PIGF ratio

- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

# Pre-eclampsia management for optimal course of care

Pre-eclampsia is a complication of pregnancy. Left untreated, it can lead to life threatening conditions. Avoiding pre-eclampsia would bring substantial improvements to maternal and fetal health.

### What is the role of angiogenic factors?

PIGF and sFlt-1 are found to be key factors in the pathophysiology of pre-eclampsia. [4] Serum levels of PIGF and sFlt-1 are altered in women with pre-eclampsia compared to those with uncomplicated pregnancies. In pregnancies that develop pre-eclampsia, maternal serum placental growth factor (PIGF) levels decrease significantly, while soluble fms-like tyrosine kinase 1 (sFlt-1) levels increase several weeks prior to clinical symptom onset.<sup>[4]</sup>

Thus, PIGF and sFlt-1 are important biomarkers used to identify high risk women that are likely to develop preterm pre-eclampsia later in their pregnancy and to predict the onset of pre-eclampsia. Biomarker levels are also found to be correlating with severity of disease. During the 1st trimester sFlt-1 levels are not predictive for the onset of preterm pre-eclampsia.<sup>[4]</sup>



#### Introduction

- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

## 1st Trimester: Screening and prevention of preterm pre-eclampsia


With pre-eclampsia screening, women with increased risk for preterm pre-eclampsia can be identified. This enables timely intervention for reducing the incidence of pre-eclampsia and enables efficient patient care thru pregnancy.

Traditional methods (Maternal risk factors) have poor sensitivity and specificity to predict pre-eclampsia. Better detection rate could be achieved with PIGF together with other relevant clinical information (maternal history, mean arterial blood pressure and uterine artery pulsatility index) for pre-eclampsia screening. Decreased PIGF levels predict future development of preterm PE.<sup>[1,2]</sup>

## 2nd and 3rd Trimester: Short term prediction and aid in diagnosis

Women with signs or symptoms of pre-eclampsia do not always develop pre-eclampsia. Angiogenic markers can be used to help identify women with increased risk for developing pre-eclampsia in the coming days.

It has been shown that decreased levels of PIGF or increased sFlt-1/PIGF ratio (increased sFlt-1 and decreased PIGF) can predict the subsequent onset of pre-eclampsia, and improve the clinical management and decision making (risk stratification) with symptomatic women.






- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.



sFlt-1/PIGF ratio

serum



- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

## Second and third trimester: Shortterm prediction and aid in diagnosis

After week 20 of gestation, PIGF based testing improves pre-eclampsia management for symptomatic women

#### Short term prediction and aid in diagnosis

During the 2nd and 3rd trimesters sFlt-1 and PIGF are both predictive and diagnostic for pre-eclampsia. It has been shown that increased levels of sFlt-1 and decreased levels of PIGF in maternal serum can predict the subsequent onset of pre-eclampsia.<sup>[4, 5]</sup>

Determining serum PIGF concentration, used as a single marker, or sFlt-1 and PIGF, used as a ratio, improve the clinical management and decision making (risk stratification) with women showing signs and symptoms of pre-eclampsia.<sup>[4, 5]</sup>

#### When is PIGF based testing valuable?

- For testing women with signs and symptoms of pre-eclampsia after week 20 of gestation
- To help Rule-out and Rule-in suspected pre-eclampsia
- To monitor women that are at high risk for pre-eclampsia
- To confirm clinical suspection of pre-eclampsia with symptomatic women and/or to confirm unclear diagnosis of pre-eclampsia
- Serum concentrations of sFlt-1 and PIGF can differentiate healthy women from women with pre-eclampsia. Changes in sFlt-1 and PIGF levels reflect the severity of the disease.<sup>[4, 5]</sup>

#### What are the benefits of PIGF based testing in clinical care?

- To avoid unnecessary hospitalization that is associated with cost-savings
- To enable improved prognosis, triage & diagnosis leading to better maternal & neonatal outcomes

Decisions regarding delivery are not based solely on the PIGF based assays, but are always made in context of other clinical signs and symptoms.

#### Two alternatives - PIGF as a single marker or sFlt-1/PIGF ratio

PIGF alone compared to sFlt-1/PIGF ratio for pre-eclampsia rule-in and rule-out has a comparable performance, and both options are equally recommended for clinical use. In addition to sFlt-1/PIGF ratio, PLGF alone, with concentration based cut-offs, could provide more simpler and affordable alternative to dual biomarker testing. <sup>[6, 7, 8]</sup>

Using PIGF has additional advantages. Studies have shown that PIGF is a good marker (decreased serum PIGF level) for identifying pregnancies with placental insufficiency including fetal growth restriction and/or stillbirth.<sup>[9, 10, 11]</sup>


- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

## Short term prediction and aid in diagnosis





GA= gestational age

- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

# Comprehensive offering covering all trimesters

Revvity offers compehensive solutions for pre-eclampsia management for all trimesters.

#### **PIGF 1-2-3<sup>™</sup> - unique kit for all trimesters**

Revvity's high-sensitivity PIGF 1-2-3<sup>™</sup> kit is the only assay that can offer the level of accuracy and precision that was required for 1T prediction and prevention of pre-eclampsia by the ground-breaking ASPRE trial.

The kit is used for screening pregnant women for pre-eclampsia in the first trimester of pregnancy. The same PIGF kit can also be used for short term prediction and aid in diagnosis for pre-eclampsia in the 2T/3T, as a single marker or together with sFlt-1 as a ratio of concentrations.

Possibility to use only one kit through whole pregnancy from screening to management brings cost-benefits as well as ease and effectiveness for laboratories.

#### **DELFIA®** Xpress sFlt-1 kit

The kit is used with the PIGF kit for the determining the sFlt-1/PIGF ratio. The ratio of sFlt-1/PIGF may be used as an aid in diagnosis of pre-eclampsia and for short term prediction of suspected pre-eclampsia together with other biochemical and clinical information.

#### **Native Serum Controls**

Lyophilized human serum controls for both PIGF and sFlt-1 allow performance monitoring within the clinically relevant range. Two levels of controls are sold as separate products for both PIGF and sFlt-1 assays.

#### LifeCycle software

With LifeCycle<sup>™</sup> software you can follow up the patient from 1T preeclampsia risk assessment to 2T/3T pre-eclampsia management. For ratio calculation, sFlt-1 and PIGF concentrations are transferred automatically from the DELFIA® Xpress platform to the LifeCycle<sup>™</sup> software, so

there is no need for manual typing.

LifeCycle software enables monitoring pre-eclampsia status with PIGF concentration or the sFlt-1/PIGF ratio and the ratio results can be linked to the same patients' other results in LifeCycle<sup>™</sup> software. The cut-offs for pre-eclampsia management are adjustable.



Introduction

- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA<sup>®</sup> Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

## Dedicated random access prenatal screening platform from the world leader in prenatal testing

DELFIA® Xpress streamlines workflows in laboratories and clinics providing prenatal screening ser-vices. Already in use in more than 50 countries, DELFIA® Xpress offers a range of benefits critical for operational efficiency.

- The speed and flexibility of random access
- Simplicity and ease of use with up-to-date software design
- The security associated with barcoded reagents and samples to ensure positive identification
- The reassurance from using reliable, proven DELFIA chemistry
- Smart connectivity to Revvity's clinically validated LifeCycle<sup>™</sup> prenatal screening software with MFH risk calculation engine and statistical analysis tool
- The flexibility to support connections to 3rd party software such as Viewpoint and Astraia

### Leaders in prenatal screening for over 30 years

Revvity provides state-of-the-art solutions to benefit maternal and fetal health. Our solutions comprise instruments, reagents and screening management software, all based on our broad-ranging expertise and understanding of today's needs.

We are the global leader in products for detecting fetal anomalies during pregnancy, and our platforms are used in more than 50 countries to perform some 10 million prenatal risk assessments per year. DELFIA® Xpress has become the platform of choice in many parts of the world.

The DELFIA® Xpress instrument and first trimester assays are approved by the Fetal Medicine Foundation (FMF).



- Introduction
- 1T / 2T / 3T
- PIGF based testing
- Short term prediction and aid in diagnosis
- Comprehensive offering
- DELFIA® Xpress
- References
- Contact us

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.

Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

## References

- 1. O'Gorman N et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756-760
- 2. Rolnik D et al. Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation Ultrasound Obstet Gynecol 2017; 50: 551–556
- 3. Levine R J et al. Circulating Angiogenic Factors and the Risk of Preeclampsia, N Engl J Med 2004; 350:672-683
- 4. Lecarpentier E, Tsatsaris V. Angiogenic balance (sFlt-1/PIGF) and preeclampsia. Ann Endocrinol (Paris). 2016;77(2):97-100.
- 5. Zeisler H et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia, N Engl J Med. 2016; 374(1):13-22
- 6. McCarthy F et al. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm preeclampsia: the COMPARE study. Ultrasound Obstet Gynecol 2019; 53: 62-67
- 7. Giblin L et al. Rule-in thresholds for DELFIA Xpress PIGF 1-2-3 test for suspected pre-eclampsia. Pregnancy Hypertens. 2020;21:35-37.
- 8. Bremner L et al. Rule-in and rule-out of pre-eclampsia using DELFIA Xpress PIGF 1-2-3 and sFlt-1: PIGF ratio. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2022; 27: 96–102
- 9. Sherrell H et al. Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. Eur J Obstet Gynecol Reprod Biol. 2018; 225: 26–34.
- 10. Benton S J et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016: 42; 1-8.
- 11. Townsend R et al. Prediction of stillbirth: an umbrella review of evaluation of prognostic variables. BJOG. 2021; 128(2): 238-250.



www.revvity.com



Revvity, Inc. 940 Winter Street, Waltham, MA 02451 USA (800) 762-4000 | www.revvity.com

For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.

1125464